IQVIA Holdings Inc (IQV)vsMyriad Genetics Inc (MYGN)
IQV
IQVIA Holdings Inc
$165.64
-0.27%
HEALTHCARE · Cap: $28.11B
MYGN
Myriad Genetics Inc
$4.68
+1.52%
HEALTHCARE · Cap: $435.75M
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 1878% more annual revenue ($16.31B vs $824.50M). IQV leads profitability with a 8.3% profit margin vs -44.4%. IQV appears more attractively valued with a PEG of 0.97. IQV earns a higher WallStSmart Score of 72/100 (B).
IQV
Strong Buy72
out of 100
Grade: B
MYGN
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+49.1%
Fair Value
$348.46
Current Price
$165.64
$182.82 discount
Intrinsic value data unavailable for MYGN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 21 in profit
Growing faster than its price suggests
Earnings expanding 23.6% YoY
Reasonable price relative to book value
Areas to Watch
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -68.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bull Case : MYGN
The strongest argument for MYGN centers on Price/Book. PEG of 1.40 suggests the stock is reasonably priced for its growth.
Bear Case : IQV
The primary concerns for IQV are Altman Z-Score.
Bear Case : MYGN
The primary concerns for MYGN are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
IQV profiles as a value stock while MYGN is a turnaround play — different risk/reward profiles.
MYGN carries more volatility with a beta of 1.93 — expect wider price swings.
IQV is growing revenue faster at 10.3% — sustainability is the question.
IQV generates stronger free cash flow (561M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (72/100 vs 44/100) and 10.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Myriad Genetics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?